BlackRock Fund Advisors’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

BlackRock Fund Advisors’s Portfolio FOMX Stock Details FOMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$5.68M	Buy	511,799 +100,072	+24%	+$942K	﹤0.01%	2872
2016 Q3	$3.81M	Buy	411,727 +26,583	+7%	+$222K	﹤0.01%	2981
2016 Q2	$2.45M	Sell	385,144 -596,671	-61%	-$3.96M	﹤0.01%	3140
2016 Q1	$6.4M	Buy	981,815 +13,510	+1%	+$87.1K	﹤0.01%	2611
2015 Q4	$7.85M	Buy	968,305 +371,311	+62%	+$2.78M	﹤0.01%	2586
2015 Q3	$4.38M	Buy	596,994 +4,120	+0.7%	+$42K	﹤0.01%	2866
2015 Q2	$6.08M	Buy	592,874 +573,615	+2,978%	+$6.34M	﹤0.01%	2807
2015 Q1	$178K	Buy	19,259 +11,464	+147%	+$103K	﹤0.01%	3508
2014 Q4	$55K	Buy	+7,795	New	+$44.6K	﹤0.01%	3670

Other funds holding FOMX

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock Fund Advisors's FOMX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) stake by 24% in Q4 2016, buying an estimated $942K and bringing the position to 511,799 shares worth $5.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2872.

BlackRock Fund Advisors first reported a position in FOMX in Q4 2014 and has held it in 9 quarters since. The position peaked at $7.85M in Q4 2015. 64 funds tracked by Wall St. Rank hold FOMX as of Q4 2016.

BlackRock Fund Advisors held 511,799 shares of Foamix Pharmaceuticals Ltd. Ordinary Shares worth $5.68M as of Q4 2016.
BlackRock Fund Advisors bought 100,072 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q4 2016, an estimated $942K.
Foamix Pharmaceuticals Ltd. Ordinary Shares made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2872 holding.
BlackRock Fund Advisors first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q4 2014 and has held it in 9 quarters since.
BlackRock Fund Advisors's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $7.85M in Q4 2015.
64 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.